시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 중추성 성조숙증 시장 보고서(2025년)
Central Precocious Puberty Global Market Report 2025
상품코드 : 1824608
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

중추성 성조숙증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.4%를 나타내 30억 2,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 소아 건강 관리 통합, 맞춤형 의료로의 전환, 부모 교육 및 의식 향상 프로그램, 장시간 작용 치료 옵션의 개발, 조기 진단 및 개입으로 인한 것으로 예측됩니다. 예측 기간의 주요 동향으로는 장기간 작용하는 제형, 환자 중심 접근법, 원격 의료 및 원격 모니터링, 개인화 치료 접근법, 공동 관리 모델, 모니터링을 위한 디지털 건강 도구 등이 있습니다.

향후 5년간의 성장률 9.4%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 프랑스와 독일에서 개발된 GnRH 아날로그 임플란트와 사춘기 억제제의 가격을 상승시켜 개입 지연과 소아 전문 의료비의 상승을 초래하여 미국의 소아 내분비학에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

연구개발 이니셔티브의 급증은 당분간 중추성 성조숙증 시장 확대를 촉진할 것으로 예측됩니다. R&D 활동에는 기존 지식, 제품, 서비스 및 절차를 혁신하고 개선하기 위해 조직이 수행하는 다양한 프로세스가 포함됩니다. 중추성 성조숙증(CPP)의 맥락에서 이러한 노력은 병리학의 이해를 추진하고, 진단 및 치료 옵션을 정교하게 하며, 전체 환자 케어를 개선하는 데 크게 기여하고 있습니다. 예를 들어, 룩셈부르크에 본사를 둔 비영리 단체인 유로스타트는 2022년 유럽정부의 연구개발(R&D) 할당을 약 1,261억 5,300만 미 달러(1,173억 6,800만 유로)로 보고했으며, 이는 전년 1,197억 3,000만 달러(1,113억 9,300만 유로)에서 5.4% 증가한 것으로 나타났습니다. 게다가 2022년 1월에 약사 전문가 협회(Regulatory Affairs Professionals Society)가 발표한 데이터에 따르면 2021년 미국 식품의약국(FDA)이 승인한 37품목의 의약품 중 74%가 신속화 경로를 거치며 전년 수치에서 상승하고 있음이 밝혀졌습니다. 이러한 연구개발의 급증은 중추성 성조숙증 시장 성장 촉진요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Central precocious puberty is a medical condition characterized by the early onset of the normal sexual development process in both girls and boys. It occurs when the initiation of sexual development happens earlier than the typical age range, without any underlying medical problem or identifiable reason for early puberty.

The main drugs used in the treatment of central precocious puberty include leuprolide acetate, triptorelin, histrelin acetate, and nafarelin. Leuprolide acetate, a synthetic medication belonging to the gonadotropin-releasing hormone (GnRH) agonists class, is commonly used in reproductive medicine and endocrinology. These drugs can be administered through various routes, such as parenteral, subcutaneous, intramuscular, and others. They are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, serving end-users such as hospitals, specialty clinics, homecare, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The central precocious puberty market research report is one of a series of new reports from The Business Research Company that provides central precocious puberty market statistics, including central precocious puberty industry global market size, regional shares, competitors with a central precocious puberty market share, detailed central precocious puberty market segments, market trends and opportunities, and any further data you may need to thrive in the central precocious puberty industry. This central precocious puberty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The central precocious puberty market size has grown strongly in recent years. It will grow from $1.97 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increased prevalence of central precocious puberty, improvements in treatment approaches, impact of environmental factors, increased pediatric endocrinology services, parental concerns and seeking medical attention, patient advocacy efforts.

The central precocious puberty market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to pediatric healthcare integration, shift towards personalized medicine, parental education and awareness programs, development of longer-acting treatment options, early diagnosis and intervention. Major trends in the forecast period include long-acting formulations, patient-centric approaches, telehealth and remote monitoring, individualized treatment approaches, collaborative care models, digital health tools for monitoring.

The forecast of 9.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pediatric endocrinology by inflating prices of GnRH analog implants and puberty-blocking medications developed in France and Germany, resulting in delayed interventions and higher pediatric specialty care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An upsurge in research and development initiatives is anticipated to propel the expansion of the central precocious puberty market in the foreseeable future. Research and development activities encompass a spectrum of processes undertaken by organizations to innovate and improve existing knowledge, products, services, or procedures. Within the context of central precocious puberty (CPP), these efforts significantly contribute to advancing comprehension of the condition, refining diagnostic and treatment options, and elevating overall patient care. For example, Eurostat, a Luxembourg-based non-profit organization, reported an allocation of approximately $126,153 million (€117,368 million) for research and development (R&D) by the European government in 2022, marking a 5.4% increase from the previous year's $119,730 million (€111,393 million). Additionally, data from the Regulatory Affairs Professionals Society in January 2022 highlighted that 74% of the 37 drugs approved by the US Food and Drug Administration (FDA) in 2021 underwent expedited pathways, demonstrating a rise from the previous year's figures. This surge in research and development undertakings is a key driver of growth within the central precocious puberty market.

Rising healthcare expenditure is expected to drive the growth of the central precocious puberty (CPP) market. Healthcare expenditure encompasses the total funds allocated for healthcare goods and services, including medical equipment, hospital services, physician care, prescription drugs, and public health activities. Increased spending in healthcare benefits the CPP market by enhancing diagnosis and treatment, reducing overall healthcare costs, improving patients' quality of life, supporting the development of new treatments, and raising awareness about CPP. For example, in March 2022, the Centers for Medicare & Medicaid Services projected in its National Health Expenditure (NHE) report for 2021-2030 that national health spending would increase by an average of 5.1% annually, reaching approximately $6.8 trillion by 2030. Additionally, Medicare expenditures are expected to grow at an annual rate of 7.2%, while Medicaid spending is predicted to rise by 5.6% per year during the same period. This increase in healthcare expenditure is thus expected to fuel the growth of the CPP market.

Prominent entities within the central precocious puberty market are strategically concentrating on the development of innovative injections, such as leuprolide acetate injections, to secure a competitive advantage. Leuprolide acetate injection, a synthetic hormone emulating a natural hormone, is utilized in treating various medical conditions, including advanced prostate cancer and the premature onset of puberty. A case in point is Cipla Limited, an India-based pharmaceutical company, which introduced Leuprolide Acetate Injection Depot 22.5 mg in November 2022 for addressing central precocious puberty and advanced prostate cancer. This injection, provided in a single-dose device carrying 22.5 mg of leuprolide acetate, offers a three-month treatment duration. Comprising lyophilized microspheres in a single-dose vial, the kit includes an easy-to-use MIXJECT transfer device and a prefilled syringe containing 2 mL of 0.8% mannitol solution.

In June 2022, Eversana Life Science Services LLC, a prominent US-based life sciences company, entered into a partnership with Accord BioPharma aimed at facilitating the introduction of CAMCEVI, specifically designed for the treatment of advanced prostate cancer in adults within the United States. Although primarily intended for advanced prostate cancer, CAMCEVI (leuprolide mesylate) is also employed in addressing central precocious puberty. This synthetic hormone closely mimics a natural hormone produced in the brain and serves as a treatment for several medical conditions, including central precocious puberty. CAMCEVI stands out as the initial sterile leuprolide formulation for subcutaneous injection, packaged in a pre-filled syringe, eliminating the need for mixing before administration. Accord BioPharma, a US-based pharmaceutical company specializing in the development and marketing of treatments for various conditions, including central precocious puberty, is a key collaborator in this endeavor.

Major companies operating in the central precocious puberty market report are Cipla Limited, Cigna Group, Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Molina Healthcare Inc., Sun Pharmaceutical Industries Ltd., Ipsen Ltd., Ferring Pharmaceuticals Private Limited, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Piramal Enterprises Limited, Livzon Pharmaceutical Group Inc., Salvavidas Pharmaceutical Pvt. Ltd., Actiza Pharmaceutical Private Limited, The Bachem Group, Arbor Pharmaceuticals LLC, Genentech Inc., Antares Pharma Inc., Tolmar Pharmaceuticals Inc., Debiopharm Group, AmbioPharm Inc., Foresee Pharmaceuticals Co. Ltd., Manus Aktteva Biopharma LLP, Midas Pharma GmbH, LGM Pharma LLC, Varian Pharmed Group, Shenzhen JYMed Technology Co. Ltd.

North America was the largest region in the central precocious puberty market in 2024. The regions covered in the central precocious puberty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central precocious puberty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The central precocious puberty market consists of revenues earned by entities by providing GnRH analogue therapy, histrelin implant, and surgeries and radiations. The market value includes the value of related goods sold by the service provider or included within the service offering. The central precocious puberty market also includes sales of goserelin, gonadorelin, and buserelin, and spironolactone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Precocious Puberty Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central precocious puberty market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for central precocious puberty ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central precocious puberty market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Central Precocious Puberty Market Characteristics

3. Central Precocious Puberty Market Trends And Strategies

4. Central Precocious Puberty Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Central Precocious Puberty Growth Analysis And Strategic Analysis Framework

6. Central Precocious Puberty Market Segmentation

7. Central Precocious Puberty Market Regional And Country Analysis

8. Asia-Pacific Central Precocious Puberty Market

9. China Central Precocious Puberty Market

10. India Central Precocious Puberty Market

11. Japan Central Precocious Puberty Market

12. Australia Central Precocious Puberty Market

13. Indonesia Central Precocious Puberty Market

14. South Korea Central Precocious Puberty Market

15. Western Europe Central Precocious Puberty Market

16. UK Central Precocious Puberty Market

17. Germany Central Precocious Puberty Market

18. France Central Precocious Puberty Market

19. Italy Central Precocious Puberty Market

20. Spain Central Precocious Puberty Market

21. Eastern Europe Central Precocious Puberty Market

22. Russia Central Precocious Puberty Market

23. North America Central Precocious Puberty Market

24. USA Central Precocious Puberty Market

25. Canada Central Precocious Puberty Market

26. South America Central Precocious Puberty Market

27. Brazil Central Precocious Puberty Market

28. Middle East Central Precocious Puberty Market

29. Africa Central Precocious Puberty Market

30. Central Precocious Puberty Market Competitive Landscape And Company Profiles

31. Central Precocious Puberty Market Other Major And Innovative Companies

32. Global Central Precocious Puberty Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Precocious Puberty Market

34. Recent Developments In The Central Precocious Puberty Market

35. Central Precocious Puberty Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기